Cargando…

Clinical Overview of MDM2/X-Targeted Therapies

MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation and inhibiting its transcriptional activity. Both MDM2 and MDMX function as powerful oncogenes and are commonly ove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burgess, Andrew, Chia, Kee Ming, Haupt, Sue, Thomas, David, Haupt, Ygal, Lim, Elgene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728205/ https://www.ncbi.nlm.nih.gov/pubmed/26858935 http://dx.doi.org/10.3389/fonc.2016.00007

Ejemplares similares

The role of MDM2 and MDM4 in breast cancer development and prevention
por: Haupt, Sue, et al.
Publicado: (2017)

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
por: Portman, Neil, et al.
Publicado: (2020)

New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers
por: Wolyniec, Kamil, et al.
Publicado: (2013)

Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways
por: Haupt, Sue, et al.
Publicado: (2016)

p53 Calls upon CIA (Calcium Induced Apoptosis) to Counter Stress
por: Haupt, Sue, et al.
Publicado: (2015)

The long and the short of it: the MDM4 tail so far
por: Haupt, Sue, et al.
Publicado: (2019)

Corrigendum to ‘The long and the short of it: the MDM4 tail so far’
por: Haupt, Sue, et al.
Publicado: (2019)

Regulation of Mutant p53 Protein Expression
por: Vijayakumaran, Reshma, et al.
Publicado: (2015)

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
por: Portman, Neil, et al.
Publicado: (2021)

Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins
por: Haupt, Ygal, et al.
Publicado: (2016)

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
por: Miles, Xanthene, et al.
Publicado: (2021)

P53 at the start of the 21st century: lessons from elephants
por: Haupt, Sue, et al.
Publicado: (2017)

Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex Disparity
por: Haupt, Sue, et al.
Publicado: (2021)

Establishing the Link between X-Chromosome Aberrations and TP53 Status, with Breast Cancer Patient Outcomes
por: Caramia, Franco, et al.
Publicado: (2023)

New insights on the regulation of INK4/ARF locus expression
por: Gamell, Cristina, et al.
Publicado: (2017)

Restoring PML tumor suppression to combat cancer
por: Wolyniec, Kamil, et al.
Publicado: (2012)

Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network
por: Haupt, Sue, et al.
Publicado: (2019)

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
por: Mejía-Hernández, Javier Octavio, et al.
Publicado: (2022)

P53: A Guardian of Immunity Becomes Its Saboteur through Mutation
por: Agupitan, Arjelle Decasa, et al.
Publicado: (2020)

Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
por: Traweek, Raymond S., et al.
Publicado: (2022)

Inhibiting the system x(C)(−)/glutathione axis selectively targets cancers with mutant-p53 accumulation
por: Liu, David S., et al.
Publicado: (2017)

A Critical Overview of Targeted Therapies for Glioblastoma
por: Jain, Kewal K.
Publicado: (2018)

MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor
por: Jiang, Qiyu, et al.
Publicado: (2021)

TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
por: Freudenstein, Donald, et al.
Publicado: (2020)

Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
por: AbuHammad, Shatha, et al.
Publicado: (2019)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Reciprocal Induction of MDM2 and MYCN in Neural and Neuroendocrine Cancers
por: Tran, Hung N., et al.
Publicado: (2020)

Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers
por: Cassinelli, Giuliana, et al.
Publicado: (2022)

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews
por: van Leeuwen, Marina T, et al.
Publicado: (2018)

Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status
por: Lama, Rati, et al.
Publicado: (2022)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012)

Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
por: Taylor, Olivia G., et al.
Publicado: (2019)

De novo dedifferentiated SDH-deficient gastrointestinal stromal tumor with MDM2 amplification: case report and literature review
por: Gong, Qi-Xing, et al.
Publicado: (2023)

Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review
por: Ardolino, Luke, et al.
Publicado: (2021)

Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis
por: Masaldan, Shashank, et al.
Publicado: (2017)

Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report
por: Williams, Scott G., et al.
Publicado: (2020)

Ozone therapy for high-grade glioma: an overview
por: Yanchu, Li, et al.
Publicado: (2023)

Length matters: C-terminal tails regulate Mdm2–MdmX complexes
por: Poyurovsky, Masha V.
Publicado: (2012)

Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells
por: Egorova, Olga, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4fkf7vbe41hd54e0rdiscldt5m